Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

NCT02924064 Phase 3 COMPLETED Results posted

This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with metformin.

Details

Lead sponsor	Tanabe Pharma Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	247
Start date	2016-09

Conditions

• Type 2 Diabetes Mellitus

Interventions

• Teneligliptin 20mg
• Placebo
• Metformin ≥ 1000 mg

Primary outcomes

• The Changes in HbA1c at Week 24 — at Day 1(baseline) and Week 24
  The change in HbA1c from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.

Countries

China